Correlation Between Krebs Biochemicals and Indraprastha Medical

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Krebs Biochemicals and Indraprastha Medical at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Krebs Biochemicals and Indraprastha Medical into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Krebs Biochemicals and and Indraprastha Medical, you can compare the effects of market volatilities on Krebs Biochemicals and Indraprastha Medical and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Krebs Biochemicals with a short position of Indraprastha Medical. Check out your portfolio center. Please also check ongoing floating volatility patterns of Krebs Biochemicals and Indraprastha Medical.

Diversification Opportunities for Krebs Biochemicals and Indraprastha Medical

0.62
  Correlation Coefficient

Poor diversification

The 3 months correlation between Krebs and Indraprastha is 0.62. Overlapping area represents the amount of risk that can be diversified away by holding Krebs Biochemicals and and Indraprastha Medical in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Indraprastha Medical and Krebs Biochemicals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Krebs Biochemicals and are associated (or correlated) with Indraprastha Medical. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Indraprastha Medical has no effect on the direction of Krebs Biochemicals i.e., Krebs Biochemicals and Indraprastha Medical go up and down completely randomly.

Pair Corralation between Krebs Biochemicals and Indraprastha Medical

Assuming the 90 days trading horizon Krebs Biochemicals and is expected to under-perform the Indraprastha Medical. But the stock apears to be less risky and, when comparing its historical volatility, Krebs Biochemicals and is 1.12 times less risky than Indraprastha Medical. The stock trades about -0.24 of its potential returns per unit of risk. The Indraprastha Medical is currently generating about 0.11 of returns per unit of risk over similar time horizon. If you would invest  49,420  in Indraprastha Medical on October 12, 2024 and sell it today you would earn a total of  3,105  from holding Indraprastha Medical or generate 6.28% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthSignificant
Accuracy100.0%
ValuesDaily Returns

Krebs Biochemicals and  vs.  Indraprastha Medical

 Performance 
       Timeline  
Krebs Biochemicals and 

Risk-Adjusted Performance

5 of 100

 
Weak
 
Strong
Modest
Compared to the overall equity markets, risk-adjusted returns on investments in Krebs Biochemicals and are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. Despite fairly unsteady fundamental drivers, Krebs Biochemicals demonstrated solid returns over the last few months and may actually be approaching a breakup point.
Indraprastha Medical 

Risk-Adjusted Performance

7 of 100

 
Weak
 
Strong
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Indraprastha Medical are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. In spite of rather unsteady fundamental indicators, Indraprastha Medical exhibited solid returns over the last few months and may actually be approaching a breakup point.

Krebs Biochemicals and Indraprastha Medical Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Krebs Biochemicals and Indraprastha Medical

The main advantage of trading using opposite Krebs Biochemicals and Indraprastha Medical positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Krebs Biochemicals position performs unexpectedly, Indraprastha Medical can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Indraprastha Medical will offset losses from the drop in Indraprastha Medical's long position.
The idea behind Krebs Biochemicals and and Indraprastha Medical pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.

Other Complementary Tools

Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Commodity Directory
Find actively traded commodities issued by global exchanges
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Technical Analysis
Check basic technical indicators and analysis based on most latest market data